고형암 (전체) · PD-1 / PD-L1

24개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved24 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleMerckApproved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1669Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyCurated CoreFDAstaleBeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Upper Tract Urothelial Carcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#UpperTractUrothelialCarcinoma+1
Trials 12Status Recruiting
CGTLimited DatastaleAllife Medical Science and Tech…Phase 1

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

Solid Tumor · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Active
AntibodyLimited DatastaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 2Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleGustave Roussy, Cancer Campus, …Phase 2

atezolizumab (Tecentriq, Anti-PD-L1 antibody atezolizumab)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#PatientsWithMetastaticTumoursCol+3
Trials 1Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous aPD-L1 armored anti-CD22 CAR T cells (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Solid Tumor, Adult; Cervical Cancer · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
ADCLimited DatastaleFeng LiuPhase 2

Becotatug Vedotin Combined with PD-1 Inhibitor (Becotatug Vedotin Combined with PD-1 Inhibitor)

Head and Neck Squamous Cell Carcinoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

CTLA-4/PD-1 antibodies expressing mesoCAR-T (CTLA-4/PD-1 antibodies expressing mesoCAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Phase 1

Oncolytic Virus Injection（Revottack）+PD-1 (Oncolytic Virus Injection（Revottack）+PD-1)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNingbo Cancer HospitalPhase 2

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

Solid Tumor, Adult; Advanced Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#monoclonal-antibody#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →